148 related articles for article (PubMed ID: 37936544)
21. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
[TBL] [Abstract][Full Text] [Related]
22. Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
Grebely J; Dore GJ; Altice FL; Conway B; Litwin AH; Norton BL; Dalgard O; Gane EJ; Shibolet O; Nahass R; Luetkemeyer AF; Peng CY; Iser D; Gendrano IN; Kelly MM; Hwang P; Asante-Appiah E; Haber BA; Barr E; Robertson MN; Platt H
Ann Intern Med; 2022 Sep; 175(9):1221-1229. PubMed ID: 35939812
[TBL] [Abstract][Full Text] [Related]
23. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
[TBL] [Abstract][Full Text] [Related]
24. Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting.
Lafferty L; Rance J; Grebely J; Dore GJ; Lloyd AR; Treloar C;
Int J Drug Policy; 2020 Mar; 77():102693. PubMed ID: 32045828
[TBL] [Abstract][Full Text] [Related]
25. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin.
Stark K; Bienzle U; Vonk R; Guggenmoos-Holzmann I
Int J Epidemiol; 1997 Dec; 26(6):1359-66. PubMed ID: 9447418
[TBL] [Abstract][Full Text] [Related]
26. Incidence, prevalence and risk factors for hepatitis C in Danish prisons.
Søholm J; Holm DK; Mössner B; Madsen LW; Hansen JF; Weis N; Sauer AP; Awad T; Christensen PB
PLoS One; 2019; 14(7):e0220297. PubMed ID: 31348813
[TBL] [Abstract][Full Text] [Related]
27. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012021. PubMed ID: 28922449
[TBL] [Abstract][Full Text] [Related]
28. Reinfection incidence and risk among people treated for recent hepatitis C virus infection.
Martinello M; Carson JM; Van Der Valk M; Rockstroh JK; Ingiliz P; Hellard M; Nelson M; Lutz T; Bhagani S; Kim AY; Hull M; Cordes C; Moon J; Feld JJ; Gane E; Rauch A; Bruneau J; Tu E; Applegate T; Grebely J; Dore GJ; Matthews GV;
AIDS; 2023 Oct; 37(12):1883-1890. PubMed ID: 37467042
[TBL] [Abstract][Full Text] [Related]
29. Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons.
Johnson A; Shearer J; Thompson C; Jelley R; Aldridge J; Allsop C; Kerry J; Jones D; McCullough F; Miller C; Valappil M; Taha Y; Masson S; Jefferson T; Lawton C; Christensen L; McPherson S
J Viral Hepat; 2023 Dec; 30(12):914-921. PubMed ID: 37700492
[TBL] [Abstract][Full Text] [Related]
30. Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons.
Lim AG; Stone J; Hajarizadeh B; Byrne M; Chambers GM; Martin NK; Grebely J; Dore GJ; Lloyd AR; Vickerman P
Hepatology; 2021 Nov; 74(5):2366-2379. PubMed ID: 34105797
[TBL] [Abstract][Full Text] [Related]
31. The effects of needle-sharing and opioid substitution therapy on incidence of hepatitis C virus infection and reinfection in people who inject drugs.
Aitken CK; Agius PA; Higgs PG; Stoové MA; Bowden DS; Dietze PM
Epidemiol Infect; 2017 Mar; 145(4):796-801. PubMed ID: 27927256
[TBL] [Abstract][Full Text] [Related]
32. Who goes first? Understanding hepatitis C risk among injecting networks in the prison setting.
Lafferty L; Rance J; Treloar C
Drug Alcohol Depend; 2018 Feb; 183():96-101. PubMed ID: 29245104
[TBL] [Abstract][Full Text] [Related]
33. Consensus recommendations on the management of hepatitis C in Australia's prisons.
Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ
Med J Aust; 2023 Mar; 218(5):231-237. PubMed ID: 36871200
[TBL] [Abstract][Full Text] [Related]
34. A simple risk-based strategy for hepatitis C virus screening among incarcerated people in a low- to middle-income setting.
Hariri S; Sharafkhah M; Alavi M; Roshandel G; Fazel A; Amiriani T; Motamed-Gorji N; Bazazan A; Merat S; Poustchi H; Malekzadeh R
Harm Reduct J; 2020 Aug; 17(1):56. PubMed ID: 32795371
[TBL] [Abstract][Full Text] [Related]
35. An intervention to increase hepatitis C virus diagnosis and treatment uptake among people in custody in Iran.
Hariri S; Alavi M; Roshandel G; Mohammadi Z; Fazel A; Amiriani T; Bazazan A; Motamed-Gorji N; Sohrabpour A; Merat S; Poustchi H; Malekzadeh R
Int J Drug Policy; 2021 Sep; 95():103269. PubMed ID: 33991887
[TBL] [Abstract][Full Text] [Related]
36. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada.
Selfridge M; Cunningham EB; Barnett T; Drost A; Gray-Schleihauf C; Guarasci K; Lundgren K; Milne R; Grebely J; Fraser C
Int J Drug Policy; 2021 Oct; 96():103418. PubMed ID: 34538704
[TBL] [Abstract][Full Text] [Related]
37. Violence and hepatitis C transmission in prison-A modified social ecological model.
Sazzad HMS; McCredie L; Treloar C; Lloyd AR; Lafferty L
PLoS One; 2020; 15(12):e0243106. PubMed ID: 33259565
[TBL] [Abstract][Full Text] [Related]
38. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J;
Int J Drug Policy; 2017 Sep; 47():230-238. PubMed ID: 28633998
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul, Afghanistan.
Todd CS; Nasir A; Stanekzai MR; Fiekert K; Sipsma HL; Vlahov D; Strathdee SA
Harm Reduct J; 2015 Oct; 12():22. PubMed ID: 26472126
[TBL] [Abstract][Full Text] [Related]
40. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.
Tsui JI; Evans JL; Lum PJ; Hahn JA; Page K
JAMA Intern Med; 2014 Dec; 174(12):1974-81. PubMed ID: 25347412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
